Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis

Preeti Malik, Urvish Patel, Deep Mehta, Nidhi Patel, Raveena Kelkar, Muhammad Akrmah, Janice L Gabrilove, Henry Sacks, Preeti Malik, Urvish Patel, Deep Mehta, Nidhi Patel, Raveena Kelkar, Muhammad Akrmah, Janice L Gabrilove, Henry Sacks

Abstract

Objective: To evaluate association between biomarkers and outcomes in COVID-19 hospitalised patients. COVID-19 pandemic has been a challenge. Biomarkers have always played an important role in clinical decision making in various infectious diseases. It is crucial to assess the role of biomarkers in evaluating severity of disease and appropriate allocation of resources.

Design and setting: Systematic review and meta-analysis. English full text observational studies describing the laboratory findings and outcomes of COVID-19 hospitalised patients were identified searching PubMed, Web of Science, Scopus, medRxiv using Medical Subject Headings (MeSH) terms COVID-19 OR coronavirus OR SARS-CoV-2 OR 2019-nCoV from 1 December 2019 to 15 August 2020 following Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines.

Participants: Studies having biomarkers, including lymphocyte, platelets, D-dimer, lactate dehydrogenase (LDH), C reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, procalcitonin (PCT) and creatine kinase (CK), and describing outcomes were selected with the consensus of three independent reviewers.

Main outcome measures: Composite poor outcomes include intensive care unit admission, oxygen saturation <90%, invasive mechanical ventilation utilisation, severe disease, in-hospital admission and mortality. The OR and 95% CI were obtained and forest plots were created using random-effects models. Publication bias and heterogeneity were assessed by sensitivity analysis.

Results: 32 studies with 10 491 confirmed COVID-19 patients were included. We found that lymphopenia (pooled-OR: 3.33 (95% CI: 2.51-4.41); p<0.00001), thrombocytopenia (2.36 (1.64-3.40); p<0.00001), elevated D-dimer (3.39 (2.66-4.33); p<0.00001), elevated CRP (4.37 (3.37-5.68); p<0.00001), elevated PCT (6.33 (4.24-9.45); p<0.00001), elevated CK (2.42 (1.35-4.32); p=0.003), elevated AST (2.75 (2.30-3.29); p<0.00001), elevated ALT (1.71 (1.32-2.20); p<0.00001), elevated creatinine (2.84 (1.80-4.46); p<0.00001) and LDH (5.48 (3.89-7.71); p<0.00001) were independently associated with higher risk of poor outcomes.

Conclusion: Our study found a significant association between lymphopenia, thrombocytopenia and elevated levels of CRP, PCT, LDH, D-dimer and COVID-19 severity. The results have the potential to be used as an early biomarker to improve the management of COVID-19 patients, by identification of high-risk patients and appropriate allocation of healthcare resources in the pandemic.

Keywords: critical care; evidence-based practice; global health; infectious disease medicine; prognosis.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow diagram of literature search and study selection process of COVID-19 outcomes and biomarkers.
Figure 2
Figure 2
Forest plot of lymphopenia for predicting the outcome in COVID-19 hospitalised patients.
Figure 3
Figure 3
Forest plot of thrombocytopenia for predicting the outcome in COVID-19 hospitalised patients.
Figure 4
Figure 4
Forest plot of elevated C reactive protein (CRP) for predicting the outcome in COVID-19 hospitalised patients.
Figure 5
Figure 5
Forest plot of elevated procalcitonin for predicting the outcome in COVID-19 hospitalised patients.
Figure 6
Figure 6
Forest plot of elevated creatine kinase (CK) for predicting the outcome in COVID-19 hospitalised patients.
Figure 7
Figure 7
Forest plot of elevated aspartate aminotransferase (AST) for predicting the outcome in COVID-19 hospitalised patients.
Figure 8
Figure 8
Forest plot of elevated alanine aminotransferase (ALT) for predicting the outcome in COVID-19 hospitalised patients.
Figure 9
Figure 9
Forest plot of elevated creatinine for predicting the outcome in COVID-19 hospitalised patients.
Figure 10
Figure 10
Forest plot of elevated D-dimer for predicting the outcome in COVID-19 hospitalised patients.
Figure 11
Figure 11
Forest plot of elevated lactate dehydrogenase (LDH) for predicting the outcome in COVID-19 hospitalised patients

References

    1. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020: World Health Organization; 2020. Available: [Accessed 9 Apr 2020].
    1. COVID-19 coronavirus pandemic: Worldometer, 2020. Available: [Accessed 20 Aug 2020].
    1. Cases in the U.S.: centers for disease control and prevention, 2020. Available: [Accessed 20 Aug 2020].
    1. Who coronavirus disease (COVID-19) Dashboard: World Health organization, 2020. Available: [Accessed 20 Aug 2020].
    1. W-j G, Z-y N, Hu Y, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.
    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology T The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly 2020;2:113–22.10.46234/ccdcw2020.032
    1. Zaim S, Chong JH, Sankaranarayanan V, et al. . COVID-19 and multiorgan response. Curr Probl Cardiol 2020;45:100618. 10.1016/j.cpcardiol.2020.100618
    1. Giacomelli A, Pezzati L, Conti F, et al. . Self-Reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 2020;71:889–90.10.1093/cid/ciaa330
    1. Pan L, Mu M, Yang P, et al. . Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115:766–73.10.14309/ajg.0000000000000620
    1. Kaur N, Gupta I, Singh H, et al. . Epidemiological and clinical characteristics of 6635 COVID-19 patients: a pooled analysis. SN Compr Clin Med 2020:1048–52.10.1007/s42399-020-00393-y
    1. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020;70:311–22.10.33588/rn.7009.2020179
    1. Whittaker A, Anson M, Harky A. Neurological manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand 2020;142:14–22.10.1111/ane.13266
    1. Patel U, Malik P, Shah D, et al. . Pre-Existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol 2020. doi:10.1007/s00415-020-10141-w. [Epub ahead of print: 08 Aug 2020].
    1. Aronson JK, Ferner RE, Review B-AG. Biomarkers-A general review. Curr Protoc Pharmacol 2017;76:9.23.1-9.23.17.10.1002/cpph.19
    1. Ruan Q, Yang K, Wang W, et al. . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846–8.10.1007/s00134-020-05991-x
    1. Guan W-J, Liang W-H, Zhao Y, W-j G, W-h L, et al. . Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. 10.1183/13993003.00547-2020
    1. Goyal P, Choi JJ, Pinheiro LC, et al. . Clinical characteristics of Covid-19 in New York City. N Engl J Med Overseas Ed 2020;382:2372–4.10.1056/NEJMc2010419
    1. Stroup DF, Berlin JA, Morton SC, et al. . Meta-Analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (moose) group. JAMA 2000;283:2008–12.10.1001/jama.283.15.2008
    1. Wells GA, Shea B, O'Connell D, et al. . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses University of Ottawa, Ontario K1J 8M5, Canada: Professor GA wells, department of epidemiology and Commuunity medicine. Available:
    1. Wang F, Hou H, Luo Y, et al. . The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020;5. doi:10.1172/jci.insight.137799. [Epub ahead of print: 21 May 2020].
    1. Yang A-P, Li H-M, Tao W-Q, et al. . Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients. Aging 2020;12:10059–69.10.18632/aging.103255
    1. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020;8:36.10.1186/s40560-020-00453-4
    1. Zhao Q, Meng M, Kumar R, et al. . Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis 2020;96:131–5.10.1016/j.ijid.2020.04.086
    1. Patel UMP, Mehta D, Shah D, et al. . Early epidemiological indicators, outcomes, and interventions of COVID-19 pandemic: a systematic review. J Glob Health 2020;10.
    1. Xu H, Zhong L, Deng J, et al. . High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8. 10.1038/s41368-020-0074-x
    1. Liao Y-C, Liang W-G, Chen F-W, et al. . Il-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002;169:4288–97.10.4049/jimmunol.169.8.4288
    1. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011;9:107. 10.1186/1741-7015-9-107
    1. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clinica Chimica Acta 2020;505:190–1.10.1016/j.cca.2020.03.004
    1. Chalmers S, Khawaja A, Wieruszewski PM, et al. . Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers. WJCCM 2019;8:74–96.10.5492/wjccm.v8.i5.74
    1. Liu F, Li L, Xu M, et al. . Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020;127:104370–70.10.1016/j.jcv.2020.104370
    1. Qin C, Zhou L, Hu Z, et al. . Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762–8.10.1093/cid/ciaa248
    1. Wang L. C-Reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020;50:332–4.10.1016/j.medmal.2020.03.007
    1. Garcia-Olivé I, Sintes H, Radua J, et al. . D-Dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir Med 2020;169:106023 10.1016/j.rmed.2020.106023
    1. Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 2018;16:231–41.10.1111/jth.13911
    1. Zhang L, Yan X, Fan Q, et al. . D-Dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020;18:1324–9.10.1111/jth.14859
    1. Yu B, Li X, Chen J, et al. . Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis 2020:1–10.10.1007/s11239-020-02171-y
    1. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1–9.10.12932/AP-200220-0772
    1. Yang L, Wang W, Wang X, et al. . Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice. Hepatology 2019;69:294–313.10.1002/hep.30203
    1. Feng G, Zheng KI, Yan Q-Q, et al. . COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8:1–7.10.14218/JCTH.2020.00018
    1. Cai Q, Huang D, Yu H, et al. . COVID-19: abnormal liver function tests. J Hepatol 2020;73:566–74.10.1016/j.jhep.2020.04.006
    1. Fan Z, Chen L, Li J, et al. . Clinical features of COVID-19-Related liver functional abnormality. Clin Gastroenterol Hepatol 2020;18:1561–6.10.1016/j.cgh.2020.04.002
    1. Chen N, Zhou M, Dong X, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507–13.10.1016/S0140-6736(20)30211-7
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506.10.1016/S0140-6736(20)30183-5
    1. Henry BM, Aggarwal G, Wong J, et al. . Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med 2020;38:1722–6.10.1016/j.ajem.2020.05.073
    1. Han Y, Zhang H, Mu S, et al. . Lactate dehydrogenase, a risk factor of severe COVID-19 patients. medRxiv 2020.
    1. Chen G, Wu D, Guo W, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620–9.10.1172/JCI137244
    1. Wu C, Chen X, Cai Y, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934 10.1001/jamainternmed.2020.0994
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020;395:1054–62.10.1016/S0140-6736(20)30566-3
    1. Chan KH, Farouji I, Abu Hanoud A, et al. . Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am J Emerg Med 2020;38:1548.e1–1548.e3.10.1016/j.ajem.2020.05.015
    1. Zhang Q, Shan KS, Minalyan A, et al. . A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis. Cureus 2020;12:e8074–e74.10.7759/cureus.8074
    1. Cheng Y, Luo R, Wang K, et al. . Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–38.10.1016/j.kint.2020.03.005
    1. Harahwa TA, Lai Yau TH, Lim-Cooke M-S, et al. . The optimal diagnostic methods for COVID-19. Diagnosis 2020. doi:10.1515/dx-2020-0058. [Epub ahead of print: 06 Jul 2020].
    1. Henry BM, de Oliveira MHS, Benoit S, et al. . Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.10.1515/cclm-2020-0369
    1. Ponti G, Maccaferri M, Ruini C, et al. . Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020;57:389–99.10.1080/10408363.2020.1770685
    1. Kermali M, Khalsa RK, Pillai K, et al. . The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci 2020;254:117788. 10.1016/j.lfs.2020.117788
    1. Wang D, Hu B, Hu C, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.10.1001/jama.2020.1585
    1. Zhang J-J, Dong X, Cao Y-Y, J-j Z, Y-y C, et al. . Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730–41.10.1111/all.14238
    1. Wang Z, Yang B, Li Q, et al. . Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020.
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.10.1016/S0140-6736(20)30566-3
    1. Zheng F, Tang W, Li H, et al. . Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020;24:3404–10.10.26355/eurrev_202003_20711
    1. Colaneri M, Sacchi P, Zuccaro V, et al. . Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill 2020;25:2000460.10.2807/1560-7917.ES.2020.25.16.2000460
    1. Zhao X-Y, Xu X-X, Yin H-S, et al. . Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis 2020;20:311. 10.1186/s12879-020-05010-w
    1. Paranjpe I, Russak A, De Freitas JK, et al. . Clinical characteristics of hospitalized Covid-19 patients in New York City. medRxiv 2020.
    1. Goyal P, Choi JJ, Pinheiro LC, et al. . Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020;382:2372–4.10.1056/NEJMc2010419
    1. Wan S, Xiang Y, Fang W, et al. . Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92:797–806.10.1002/jmv.25783
    1. Zhang J, Wang X, Jia X, et al. . Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect 2020;26:767–72.10.1016/j.cmi.2020.04.012
    1. Zheng Y, Sun L-J, Xu M, et al. . Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J Zhejiang Univ Sci B 2020;21:378–87.10.1631/jzus.B2000174
    1. Hong KS, Lee KH, Chung JH, et al. . Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J 2020;61:431–7.10.3349/ymj.2020.61.5.431
    1. Huang R, Zhu L, Xue L, et al. . Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis 2020;14:e0008280. 10.1371/journal.pntd.0008280
    1. Du R-H, Liang L-R, Yang C-Q, et al. . Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55:2000524. 10.1183/13993003.00524-2020
    1. Deng M, Qi Y, Deng L, et al. . Obesity as a potential predictor of disease severity in young COVID-19 patients: a retrospective study. Obesity 2020. doi:10.1002/oby.22943. [Epub ahead of print: 29 Jun 2020].
    1. Jang JG, Hur J, Choi EY, et al. . Prognostic factors for severe coronavirus disease 2019 in Daegu, Korea. J Korean Med Sci 2020;35:e209–e09.10.3346/jkms.2020.35.e209
    1. Khamis F, Al-Zakwani I, Al Naamani H, et al. . Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman. J Infect Public Health 2020;13:906–13.10.1016/j.jiph.2020.06.002
    1. Mikami T, Miyashita H, Yamada T, et al. . Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med 2020. doi:10.1007/s11606-020-05983-z. [Epub ahead of print: 30 Jun 2020].
    1. Shahriarirad R, Khodamoradi Z, Erfani A, et al. . Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infect Dis 2020;20:427. 10.1186/s12879-020-05128-x
    1. Wang Y, Liao B, Guo Y, et al. . Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis 2020;710.1093/ofid/ofaa187
    1. Zhang G, Hu C, Luo L, et al. . Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 2020;127:104364.10.1016/j.jcv.2020.104364
    1. Jiang H, Guo W, Shi Z, et al. . Clinical imaging characteristics of inpatients with coronavirus disease-2019 in Heilongjiang Province, China: a retrospective study. Aging 2020;12:13860–8.10.18632/aging.103633
    1. Li X, Xu S, Yu M, et al. . Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110–8.10.1016/j.jaci.2020.04.006
    1. Wei Y, Zeng W, Huang X, et al. . Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu district, Hubei Province: a single-center descriptive study. BMC Infect Dis 2020;20:549. 10.1186/s12879-020-05252-8
    1. Xu J, Yang X, Yang L, et al. . Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care 2020;24:394.10.1186/s13054-020-03098-9
    1. Zhang S-Y, Lian J-S, Hu J-H, et al. . Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty 2020;9:85.10.1186/s40249-020-00710-6
    1. Ferguson J, Rosser JI, Quintero O, et al. . Characteristics and outcomes of coronavirus disease patients under Nonsurge conditions, Northern California, USA, March-April 2020. Emerg Infect Dis 2020;26:1679–85.10.3201/eid2608.201776

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe